RxDoctor Payments Data

Robin Womack, MD

Obstetrics & Gynecology · San Antonio, TXNPI 1750370821

Payments from drug & device makers

$5,009in general payments, 2019–2025

Across 191 payments — averaging $26.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$1K
  • AbbVie$576
  • Sumitomo Pharma America, Inc.$366
  • Exeltis, USA Inc.$364
  • Mayne Pharma Commercial LLC$319
  • Astellas Pharma US Inc$283
  • plus $2K from 31 others

What the payments were for

  • Travel & lodging$83917%
  • Food & beverage$4,08582%
  • Education$852%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,009 in reported general payments places this provider in the 80th percentile of 3,099 obstetrics & gynecology providers in Texas.

See all obstetrics & gynecology providers in Texas

Medicare billing

Part B allowed, 2024
$32,174
Medicare patients
227
Services billed
396

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PremarinEstrogens, Conjugated22$10,143
Estradiol115$6,405
ValacyclovirValacyclovir Hcl22$1,790
DottiEstradiol12$1,400
Clobetasol Propionate26$838
Estradiol (Twice Weekly)Estradiol13$623
Solifenacin Succinate21$525
ProgesteroneProgesterone, Micronized22$506
Ibandronate Sodium12$384
Medroxyprogesterone Acetate26$294
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst12$268
SprintecNorgestimate-Ethinyl Estradiol13$255
Norgestimate-Ethinyl Estradiol11$234
Alendronate Sodium13$202
Fluconazole12$27

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerPremarin$84$10,14322 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,099 obstetrics & gynecology providers in Texas.

Other obstetrics & gynecology in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →